PIERIS PHARMACEUTICALS TO PRESENT PRECLINICAL DATA FOR 4-1BB/PD-L1 BISPECIFIC PRS-344/ONC0055 AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

On October 2, 2018 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, reported that preclinical data for PRS-344/ONC0055 will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in Washington, D.C. PRS-344/ONC0055 is one of currently five programs Pieris is developing as part of its immuno-oncology collaboration with Servier.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB / PD-L1 bispecific compound for tumor localized activation of the immune system
Poster Number: P375
Date/Time: Friday, November 9, 2018, 8 AM – 8 PM EDT and Saturday, November 10, 2018, 8 AM – 8:30 PM EDT
Location: Hall E, Walter E. Washington Convention Center, Washington, DC

The poster will be made available on the Publications section of the Company’s website at www.pieris.com.